Loading clinical trials...
Loading clinical trials...
A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 mcg/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors
Conditions
Interventions
Tbo-filgrastim
Locations
9
United States
Teva Investigational Site 14029
Duarte, California, United States
Teva Investigational Site 14025
La Jolla, California, United States
Teva Investigational Site 14023
Beech Grove, Indiana, United States
Teva Investigational Site 14026
Detroit, Michigan, United States
Teva Investigational Site 14027
Chapel Hill, North Carolina, United States
Teva Investigational Site 14030
Cincinnati, Ohio, United States
Start Date
August 2, 2017
Primary Completion Date
October 30, 2017
Completion Date
October 30, 2017
Last Updated
December 13, 2022
NCT07310901
NCT06342713
NCT07401472
NCT07412353
NCT07280858
NCT07300189
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions